Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of Ritobegron in Overactive Bladder
NCT01003405Phase 3Withdrawn
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ritobegron in overactive bladder (OAB), sponsored by Kissei Pharmaceutical Co., Ltd.. Status: withdrawn.
02
Drugs
ritobegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01003405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01003405.